ATE173159T1 - Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe - Google Patents

Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe

Info

Publication number
ATE173159T1
ATE173159T1 AT93907548T AT93907548T ATE173159T1 AT E173159 T1 ATE173159 T1 AT E173159T1 AT 93907548 T AT93907548 T AT 93907548T AT 93907548 T AT93907548 T AT 93907548T AT E173159 T1 ATE173159 T1 AT E173159T1
Authority
AT
Austria
Prior art keywords
particles
drug
dosage forms
hydroxyethyl cellulose
delayed release
Prior art date
Application number
AT93907548T
Other languages
English (en)
Inventor
John W Shell
Original Assignee
Depomed Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Depomed Systems Inc filed Critical Depomed Systems Inc
Application granted granted Critical
Publication of ATE173159T1 publication Critical patent/ATE173159T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
AT93907548T 1992-03-25 1993-03-17 Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe ATE173159T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85832092A 1992-03-25 1992-03-25
US98695292A 1992-12-08 1992-12-08

Publications (1)

Publication Number Publication Date
ATE173159T1 true ATE173159T1 (de) 1998-11-15

Family

ID=27127455

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93907548T ATE173159T1 (de) 1992-03-25 1993-03-17 Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe

Country Status (9)

Country Link
EP (1) EP0632720B1 (de)
JP (2) JPH07507059A (de)
AT (1) ATE173159T1 (de)
AU (1) AU668386B2 (de)
CA (1) CA2132012C (de)
DE (1) DE69322077T2 (de)
DK (1) DK0632720T3 (de)
ES (1) ES2124303T3 (de)
WO (1) WO1993018755A1 (de)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993860A (en) * 1993-06-17 1999-11-30 Venture Lending NSADI delivery employing a powdered hydrocolloid gum obtainable from higher plants
US5549911A (en) * 1994-01-14 1996-08-27 Laboratoires Des Produits Ethiques Ethypharm Galenic form of 5-nitromidazole derivatives which is effective for the treatment of parasitoses and infections of the entire gastrointestinal tract
US5399356A (en) * 1994-03-24 1995-03-21 The Procter & Gamble Company Process for making solid dose forms containing bismuth
CA2184361C (en) * 1994-03-24 2000-12-05 Francis Bernard Chapura Solid dose forms containing bismuth
WO1995031186A1 (en) * 1994-05-13 1995-11-23 Smithkline Beecham Corporation Method and composition for increasing calcium uptake
ZA959221B (en) * 1994-11-02 1997-04-30 Janssen Pharmaceutica Nv Cisapride extended release
US5855915A (en) * 1995-06-30 1999-01-05 Baylor University Tablets or biologically acceptable implants for long-term antiinflammatory drug release
AU3290397A (en) * 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US5910319A (en) 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
ATE302597T1 (de) 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
EA002482B1 (ru) 1997-07-01 2002-06-27 Пфайзер Инк. Соли сертралина и лекарственные формы с длительным высвобождением сертралина
AP1224A (en) 1998-03-19 2003-11-14 Bristol Myers Squibb Co Biphasic controlled release delivery system for high solubility pharmaceuticals and method.
DE19934610A1 (de) * 1999-07-23 2001-01-25 Bayer Ag Schnellfreisetzende Extrudate und Verfahren zu ihrer Herstellung sowie daraus erhältliche Zubereitungen
IT1313590B1 (it) * 1999-08-03 2002-09-09 Formenti Farmaceutici Spa Composizioni a rilascio controllato di acido acetilsalicilico.
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
IL155281A0 (en) 2000-10-19 2003-11-23 Target Discovery Inc Methods for determining protein and peptide terminal sequences
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
KR20050111318A (ko) 2003-01-13 2005-11-24 다이노젠 파마세우티컬스, 인코포레이티드 기능성 장 질환을 치료하는 방법
EP1768668A2 (de) 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Multi-ppi-dosierform
US7544373B2 (en) 2007-04-02 2009-06-09 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US20080242642A1 (en) 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US7541347B2 (en) 2007-04-02 2009-06-02 Medicis Pharmaceutical Coropration Minocycline oral dosage forms for the treatment of acne
US7919483B2 (en) 2005-06-24 2011-04-05 Medicis Pharmaceutical Corporation Method for the treatment of acne
AU2006329564A1 (en) 2005-07-11 2007-07-05 Pharmena North America Inc. Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative
US8778395B2 (en) 2005-08-11 2014-07-15 Andrx Labs, Llc Diltiazem controlled release formulation and method of manufacture
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
WO2010017310A1 (en) 2008-08-06 2010-02-11 Medicis Pharmaceutical Corporation Method for the treatment of acne and certain dosage forms thereof
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
CA2758976C (en) 2009-04-20 2015-02-03 Alain Baron Chemosensory receptor ligand-based therapies
US8828953B2 (en) 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
WO2010129686A1 (en) 2009-05-05 2010-11-11 Vapogenix, Inc. Novel formulations of volatile anesthetics and methods of use for reducing inflammation
EP2603215A4 (de) 2010-08-11 2015-08-05 Philadelphia Health & Educatio Neue d3-dopamin-rezeptoragonisten zur behandlung von dyskinesien bei morbus parkinson
US9486463B2 (en) 2010-10-19 2016-11-08 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
EP2648754A4 (de) 2010-12-07 2016-02-24 Philadelphia Health & Educatio Verfahren zur hemmung von krebs-metastasen
KR20140035331A (ko) 2011-01-07 2014-03-21 엘셀릭스 테라퓨틱스 인코포레이티드 화학감각 수용체 리간드-기반 요법
US8476221B2 (en) 2011-03-18 2013-07-02 Halimed Pharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders
US9561241B1 (en) 2011-06-28 2017-02-07 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for minocycline
EP2601947A1 (de) * 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Kombinationspräparat mit fester Dosierung zur Behandlung von Erkrankungen einhergehend mit Helicobacter pylori
TWI519515B (zh) 2011-12-21 2016-02-01 諾維拉治療公司 Ｂ型肝炎抗病毒劑
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
CA2879454A1 (en) 2012-07-19 2014-01-23 Drexel University Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same
EP2950790A4 (de) 2012-08-09 2018-04-25 Dynamis Therapeutics, Inc. Verfahren zur aufrechterhaltung oder verbesserung der gesundheit, des wohlbefindens und/oder einer physiologischen funktion einer person
MX2015008773A (es) 2013-01-07 2015-11-06 Univ Pennsylvania Composiciones y metodos para tratar linfoma cutaneo de celulas t.
RU2673737C2 (ru) 2013-07-02 2018-11-29 ЭКОПЛЭНЕТ ЭНВАЙРОНМЕНТАЛ, ЭлЭлСи Композиции летучих органических веществ, обладающие антимикробной активностью
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3074049B1 (de) 2013-11-26 2020-05-06 Yale University Neuartige zellenpenetrierende zusammensetzungen und verfahren zur verwendung davon
US10258615B2 (en) 2013-12-09 2019-04-16 Thomas Jefferson University Methods of treating a neurodegenerative disease in a mammal in need thereof
US9982010B2 (en) 2014-04-07 2018-05-29 Women & Infants Hospital Of Rhode Island 7-dehydrocholesterol derivatives and methods using same
US10624917B2 (en) 2014-08-20 2020-04-21 Yale University Compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss
WO2016182968A1 (en) 2015-05-08 2016-11-17 Brown University Novel syringolin analogues and methods of making and using same
JP6995627B2 (ja) 2015-05-19 2022-02-04 イエール ユニバーシティ 病的石灰化状態を治療するための組成物およびそれを使用する方法
WO2016201288A1 (en) 2015-06-12 2016-12-15 Brown University Novel antibacterial compounds and methods of making and using same
NO346258B1 (en) 2015-06-30 2022-05-16 Neurad Ltd Novel breathing control modulating compounds, and methods of making and using same
WO2017075145A1 (en) 2015-10-28 2017-05-04 Yale University Quinoline amides and methods of using same
CA3005142A1 (en) 2015-11-20 2017-05-26 Yale University Compositions for treating ectopic calcification disorders, and methods using same
WO2017190001A1 (en) 2016-04-29 2017-11-02 The Regents Of The University Of Colorado, A Body Corporate Compounds and compositions useful for treating metabolic syndrome, and methods using same
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US20210330599A1 (en) 2016-08-01 2021-10-28 University Of Rochester Nanoparticles for Controlled Release of Anti-Biofilm Agents and Methods of Use
US11390859B2 (en) 2016-08-05 2022-07-19 Yale University Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
WO2018045229A1 (en) 2016-09-01 2018-03-08 Mebias Discovery Llc Substituted ureas and methods of making and using same
CN110114071B (zh) 2016-11-07 2023-07-04 爱彼特生物制药公司 含有取代的吡啶酮的三环化合物以及使用其的方法
WO2018136766A1 (en) 2017-01-19 2018-07-26 Temple University-Of The Commonwealth System Of Higher Education Novel bridged bicycloalkyl-substituted aminothizoles and their methods of use
WO2018172852A1 (en) 2017-03-21 2018-09-27 Arbutus Biopharma Corporation Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
JP7108018B2 (ja) 2017-04-17 2022-07-27 イエール ユニバーシティ 急性肺傷害を処置または予防する化合物、組成物および方法
US20210085796A1 (en) 2017-07-28 2021-03-25 Yale University Anticancer drugs and methods of making and using same
CN111818929A (zh) 2017-11-27 2020-10-23 由卫生与公众服务部部长代表的美利坚合众国 用于治疗和/或预防牙周疾病的化合物、组合物和方法
WO2019125184A1 (en) 2017-12-19 2019-06-27 Auckland Uniservices Limited Use of biomarker in cancer therapy
CA3089236A1 (en) 2018-01-24 2019-08-01 The Rockefeller University Antibacterial compounds, compositions thereof, and methods using same
US11091473B2 (en) 2018-05-29 2021-08-17 Acadia Pharmaceuticals Inc. Compounds for pain treatment, compositions comprising same, and methods of using same
KR20240042554A (ko) 2018-10-11 2024-04-02 사니핏 테라퓨틱스 에스.에이. 이소성 석회화의 치료를 위한 이노시톨 포스페이트
TWI827760B (zh) 2018-12-12 2024-01-01 加拿大商愛彼特生物製藥公司 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
BR112021014897A2 (pt) 2019-01-30 2021-09-28 Sanifit Therapeutics, S.A. Composto ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
WO2020159565A1 (en) 2019-02-01 2020-08-06 Cersci Therapeutics, Inc. Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent
US20200246317A1 (en) 2019-02-01 2020-08-06 Cersci Therapeutics, Inc. Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent
WO2020227603A1 (en) 2019-05-09 2020-11-12 The Feinstein Institutes For Medical Research Hmgb1 antagonist
US11555010B2 (en) 2019-07-25 2023-01-17 Brown University Diamide antimicrobial agents
EP3818983A1 (de) 2019-11-11 2021-05-12 Sanifit Therapeutics S.A. Inositol-phosphat-verbindungen zur verwendung in der behandlung, progressionshemmung oder verhinderung von kardiovaskulärer verkalkung
WO2021127456A1 (en) 2019-12-19 2021-06-24 Rain Therapeutics Inc. Methods of inhibiting epidermal growth factor receptor proteins
CA3181983A1 (en) 2020-06-09 2021-12-16 Zhiliang Cheng Soluble enpp1 or enpp3 proteins and uses thereof
EP4015494A1 (de) 2020-12-15 2022-06-22 Sanifit Therapeutics S.A. Verfahren zur herstellung von löslichen salzen von inositolphosphaten
EP4036097A1 (de) 2021-01-29 2022-08-03 Sanifit Therapeutics S.A. Ip4-4,6-substituierte derivatverbindungen
WO2024023360A1 (en) 2022-07-29 2024-02-01 Sanifit Therapeutics, S.A. Ip5 substituted compounds
WO2024023359A1 (en) 2022-07-29 2024-02-01 Sanifit Therapeutics, S.A. Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification
WO2024052895A1 (en) 2022-09-06 2024-03-14 Hadasit Medical Research Services And Development Ltd Combinations comprising psychedelics for the treatment of schizophrenia and other neuropsychiatric and neurologic disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH630257A5 (en) * 1975-03-17 1982-06-15 Hoffmann La Roche Sustained release formulation
HU179474B (en) * 1978-02-24 1982-10-28 Laszlo Gyarmati Process for preparing solid oral pharmaceutical compositons with increased length of activity and with a regulated release of the active material
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
IT1250483B (it) * 1990-08-30 1995-04-07 Eurand Int Sistema di ritardo a matrice multipla
DE9107805U1 (de) * 1991-02-22 1991-09-05 Sopar S.A. Division Pharma, Sart Dame Avelines, Be

Also Published As

Publication number Publication date
EP0632720A1 (de) 1995-01-11
CA2132012C (en) 2003-04-22
DE69322077T2 (de) 1999-04-08
DK0632720T3 (da) 1999-07-26
AU668386B2 (en) 1996-05-02
WO1993018755A1 (en) 1993-09-30
EP0632720B1 (de) 1998-11-11
CA2132012A1 (en) 1993-09-30
JPH07507059A (ja) 1995-08-03
AU3811493A (en) 1993-10-21
ES2124303T3 (es) 1999-02-01
JP2004203897A (ja) 2004-07-22
DE69322077D1 (de) 1998-12-17

Similar Documents

Publication Publication Date Title
ATE173159T1 (de) Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
FI914765A0 (fi) Foerdroejt frigoerande oral medicindosform.
ES2173891T3 (es) Sistema de liberacion pulsatil de un farmaco multiparticulado.
US3488418A (en) Sustained relief analgesic composition
ATE264670T1 (de) Eine pharmazeutische tablette charakterisiert durch hohen volumenzuwachs bei kontakt mit biologischen flüssigkeiten
NO991341L (no) Gastrisk retentiv oral medikamentell doseringsform for kontrollert frigjoring av darlig opploselige medikamenter samt anvendelse derav
FI924247A (fi) En doseringsform foer frigoerande av medicin till tarmen
KR870010866A (ko) 펄프(pulse)식 약제 전달용 투약형상체
GEP20032912B (en) Enteric Coated Pharmaceutical Tablets and Method of Manufacturing
RU97115570A (ru) Применение неорганических аэрогелей в фармации
Isaacs et al. Pancreatitis after rectal administration of 5-aminosalicylic acid
ATE211649T1 (de) Dosisform mit gesteuerter freigabe für kalium
GB1432784A (en) Orally administrable pharmaceutical compositions
BR0109917A (pt) Método de administração oral e composição para medicamentos sólidos ou suplementos dietéticos
Bhoyar et al. An overview of a gastro retentive floating drug delivery system
Gidwani et al. Factorial design and a practical approach for gastro-retentive drug delivery system
Janhavi et al. A Comprehensive Review on Gastro-Retentive Floating Drug Delivery Systems
US20200155466A1 (en) Oral Medicine Delivery Capsule
Kumar et al. Floating Drug Delivery System: A New Approach
IE33949L (en) Therapeutic composition
RU2254121C2 (ru) Плавающая таблетка
Duncan different regimes are used for treating overdoses of each drug, the manage
NO964775L (no) Fast farmasöytisk adenosinholdig preparat
Gangadharappa et al. APTI ijper
TH57760B (th) การลำเลียงยาสู่ลำไส้เล็กและลำไส้ใหญ่โดยใช้แคปซูลชนิด hpmc

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee